(PRME) Prime Medicine, Common Stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 511m USD | Total Return: 141.5% in 12m
Avg Turnover: 6.66M
Warnings
Share dilution 35.3% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
No distinct edge detected
Prime Medicine, Inc. (PRME) is a clinical-stage biotechnology company focused on developing genetic medicines through its proprietary Prime Editing platform. This technology utilizes programmable DNA binding domains and reverse transcriptase to perform precise genomic edits without creating double-stranded DNA breaks, a method intended to reduce off-target effects compared to traditional CRISPR-Cas9 techniques.
The company’s pipeline includes PM359, currently in Phase 1/2 clinical trials for Chronic Granulomatous Disease, alongside preclinical programs targeting Wilson Disease, liver-related genetic disorders, and Cystic Fibrosis. Prime Medicine operates within the high-growth gene editing sector, where companies typically rely on strategic partnerships and intellectual property licensing to fund long-term research and development cycles. The firm maintains active collaborations with Bristol Myers Squibb, the Broad Institute, and Beam Therapeutics to advance its therapeutic candidates.
To better understand how this company’s pipeline aligns with current market valuations, you may find it useful to explore the data on ValueRay.
- PM359 clinical trial data readouts drive near term market valuation
- Prime Editing platform validation determines long term intellectual property licensing revenue
- High research and development expenses necessitate future dilutive capital raises
- Strategic partnerships with Bristol Myers Squibb provide critical non-dilutive funding
- FDA regulatory pathway for novel gene editing therapies impacts commercialization timelines
| Net Income: -198.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -2.79 > 1.0 |
| NWC/Revenue: 2.52k% < 20% (prev 311.1%; Δ 2.21k% < -1%) |
| CFO/TA -0.53 > 3% & CFO -156.4m > Net Income -198.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.1m) vs 12m ago 35.31% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.30% > 50% (prev 12.68%; Δ -11.39% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.34 (Total Current Assets 137.9m - Total Current Liabilities 36.3m) / Total Assets 294.7m |
| B: -3.18 (Retained Earnings -937.5m / Total Assets 294.7m) |
| C: -0.65 (EBIT TTM -203.2m / Avg Total Assets 311.4m) |
| D: -4.30 (Book Value of Equity -937.5m / Total Liabilities 218.0m) |
| Altman-Z'' = -17.01 = D |
As of May 24, 2026, the stock is trading at USD 2.95 with a total of 1,977,055 shares traded.
Over the past week, the price has changed by +1.37%,
over one month by -25.00%,
over three months by -11.08% and
over the past year by +141.46%.
Prime Medicine, Common Stock has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy PRME.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.9 | 134.6% |
P/B = 6.3699
Revenue TTM = 4.03m USD
EBIT TTM = -203.2m USD
EBITDA TTM = -195.7m USD
Long Term Debt = 106.0m USD (estimated: total debt 114.5m - short term 8.55m)
Short Term Debt = 8.55m USD (from shortTermDebt, last quarter)
Debt = 114.5m USD (from shortLongTermDebtTotal, last quarter) (leases 114.5m already included)
Net Debt = -21.0m USD (calculated: Debt 114.5m - CCE 135.5m)
Enterprise Value = 490.2m USD (511.1m + Debt 114.5m - CCE 135.5m)
Interest Coverage Ratio = unknown (Ebit TTM -203.2m / Interest Expense TTM 0.0)
EV/FCF = -2.94x (Enterprise Value 490.2m / FCF TTM -166.8m)
FCF Yield = -34.02% (FCF TTM -166.8m / Enterprise Value 490.2m)
FCF Margin = -4.13k% (FCF TTM -166.8m / Revenue TTM 4.03m)
Net Margin = -4.92k% (Net Income TTM -198.4m / Revenue TTM 4.03m)
Gross Margin = unknown ((Revenue TTM 4.03m - Cost of Revenue TTM 49.6m) / Revenue TTM)
Tobins Q-Ratio = 1.66 (Enterprise Value 490.2m / Total Assets 294.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 114.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -160.5m (EBIT -203.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 137.9m / Total Current Liabilities 48.6m)
Debt / Equity = 1.49 (Debt 114.5m / totalStockholderEquity, last quarter 76.7m)
Debt / EBITDA = 0.11 (negative EBITDA) (Net Debt -21.0m / EBITDA -195.7m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -21.0m / FCF TTM -166.8m)
Total Stockholder Equity = 105.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.69% (Net Income -198.4m / Total Assets 294.7m)
RoE = -19.03% (Net Income TTM -198.4m / Total Stockholder Equity 1.04b)
RoCE = -17.69% (EBIT -203.2m / Capital Employed (Equity 1.04b + L.T.Debt 106.0m))
RoIC = -122.1% (out of range, set to none) (NOPAT -160.5m / Invested Capital 131.5m)
WACC = 12.41% (E(511.1m)/V(625.7m) * Re(15.19%) + D(114.5m)/V(625.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 15.19% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 30.45%
[DCF] Fair Price = unknown (Cash Flow -166.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.55 | # QB: 0
Revenue Correlation: -26.77 | Revenue CAGR: -28.68% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.25 | Chg30d=-10.01% | Revisions=-33% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.23 | Chg30d=+2.84% | Revisions=-11% | Analysts=11
EPS current Year (2026-12-31): EPS=-0.98 | Chg30d=-7.15% | Revisions=-45% | GrowthEPS=+27.5% | GrowthRev=+179.1%
EPS next Year (2027-12-31): EPS=-0.87 | Chg30d=-9.40% | Revisions=+20% | GrowthEPS=+10.9% | GrowthRev=+74.2%
[Analyst] Revisions Ratio: -45%